VC-backed Genocea Biosciences prices IPO – Fortune


According to Fortune, Genocea Biosciences has priced its IPO of 5.5 million shares at between $12 and $14 a share. The stock will trade on the NASDAQ under the ticker symbol “GNCA.” Citigroup and Cowen & Co. are the lead underwriters. Based in Cambridge, Mass., Genocea Biosciences is a developer of T-cell vaccines. Genocea’s backers include Polaris Venture Partners, Lux Ventures, Skyline Ventures, Auriga Ventures, The Bill & Melinda Gates Foundation and Morningside Ventures.

Take your pick!

  • Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
  • VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.